Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023
This bill expands the priority-review voucher program for tropical diseases to include coccidioidomycosis (also known as Valley fever). A voucher entitles the holder to have a future new drug or biological product application acted upon by the Food and Drug Administration within six months.
Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023
This bill expands the priority-review voucher program for tropical diseases to include coccidioidomycosis (also known as Valley fever). A voucher entitles the holder to have a future new drug or biological product application acted upon by the Food and Drug Administration within six months.
Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023
This bill expands the priority-review voucher program for tropical diseases to include coccidioidomycosis (also known as Valley fever). A voucher entit...